Relay Therapeutics Quick Ratio Over Time

RLAY Stock  USD 3.34  0.05  1.52%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Relay Therapeutics Performance and Relay Therapeutics Correlation.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.
  
Quick Ratio is likely to drop to 15.15 in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relay Therapeutics. If investors know Relay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relay Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.36)
Revenue Per Share
0.07
Quarterly Revenue Growth
43.279
Return On Assets
(0.28)
Return On Equity
(0.44)
The market value of Relay Therapeutics is measured differently than its book value, which is the value of Relay that is recorded on the company's balance sheet. Investors also form their own opinion of Relay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relay Therapeutics' market value can be influenced by many factors that don't directly affect Relay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relay Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relay Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relay Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Quick Ratio Analysis

Compare Relay Therapeutics and related stocks such as Stoke Therapeutics, Pliant Therapeutics, and Black Diamond Therap Quick Ratio Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
STOK0.51410.51410.51410.51410.51410.51410.51410.514143.025155.116625.726913.37417.42626.98728.047.63
PLRX1.47651.47651.47651.47651.47651.47651.47651.476512.142613.693125.067212.443814.231217.72210.905710.77
BDTX3.54893.54893.54893.54893.54893.54893.54893.548920.071531.804622.47538.87348.36816.82254.91794.67
ARVN3.71553.71553.71553.71553.71553.71553.71553.67018.51528.864814.32385.91524.1844.97944.64457.18
DAWN13.527513.527513.527513.527513.527513.527513.527513.527513.527513.527522.580733.425920.937312.71777.61067.23
TERN37.253137.253137.253137.253137.253137.253137.253137.253137.25314.48973.851824.476533.67822.390520.1516.82
APLS7.16097.16097.16097.160913.046311.88817.521127.771811.8915.67427.14736.12653.78152.5043.81413.62
IPSC27.316627.316627.316627.316627.316627.316627.316627.316627.316627.31666.350514.589810.72289.917911.4115.16
BPMC0.77640.77640.77640.77647.13699.14259.62715.98298.28528.92937.02723.55365.553.66262.79552.66
CCCC5.1585.1585.1585.1585.1585.1585.1585.1585.1582.87658.68856.35547.82386.34125.714.97
GLUE2.27382.27382.27382.27382.27382.27382.27382.27382.27382.27381.48920.95610.75235.06984.566.49
NRIX1.23821.23821.23821.23821.23821.23821.23821.23822.43876.70054.69564.52273.39826.46185.823.37
FHTX11.680311.680311.680311.680311.680311.680311.680311.680311.68031.334610.11829.43811.02674.11023.7266.51
EWTX21.239421.239421.239421.239421.239421.239421.239421.239421.239421.239429.858426.688421.220819.497819.92825.38
MLYS0.28840.28840.28840.28840.28840.28840.28840.28840.28840.28840.28842.200613.649423.764814.0218.62
CGEM25.845225.845225.845225.845225.845225.845225.845225.845225.845239.671414.823925.248121.089517.066213.530524.72

Relay Therapeutics and related stocks such as Stoke Therapeutics, Pliant Therapeutics, and Black Diamond Therap Quick Ratio description

A measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities.

My Equities

My Current Equities and Potential Positions

Relay Therapeutics
RLAY
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 3.34

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.